SCHEMBL4098264

SCHEMBL4098264

Fc1ccccc1C(Cc1cccc2cccnc12)C1CNCC[N]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
ALDH1A1 P00352 1/20 0.35
SLC6A4 P31645 6/20 0.34
SLC6A2 P23975 5/20 0.34
KCNH2 Q12809 4/20 0.34
CYP2D6 P10635 2/20 0.34
NPC1 O15118 2/20 0.34
MEN1 O00255 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 2/20 0.34
P4HB P07237 2/20 0.34
MAPT P10636 2/20 0.34
USP2 O75604 1/20 0.34
THRB P10828 1/20 0.34
REN P00797 1/20 0.34
CYP3A4 P08684 1/20 0.34
HTR2A P28223 4/20 0.32
HTR2C P28335 4/20 0.32
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4114006 0.90 HTR2A (0.38) SLC6A4SLC6A2KCNH2NPC1MEN1
SCHEMBL4106037 0.84 MEN1 (0.36) LMNAALDH1A1SLC6A4SLC6A2KCNH2
SCHEMBL4111663 0.84 SLC6A4 (0.37) SLC6A4SLC6A2KCNH2NPC1MEN1
SCHEMBL4104053 0.80 HTT (0.36) LMNASLC6A4NPC1MEN1KMT2A
SCHEMBL4111893 0.80 KMT2A (0.36) LMNAALDH1A1SLC6A4SLC6A2KCNH2
SCHEMBL4118551 0.80 CHKA (0.36) SLC6A4SLC6A2CYP2D6NPC1RAB9A
SCHEMBL4110906 0.73 CHKA (0.35) SLC6A4SLC6A2KCNH2REN
SCHEMBL4023118 0.69 SLC6A2 (0.36) ALDH1A1SLC6A4SLC6A2KCNH2CYP2D6
SCHEMBL4110744 0.67 CHKA (0.34) SLC6A4SLC6A2CYP2D6RAB9ATP53
SCHEMBL10475730 0.65 SSTR4 (0.34) LMNAALDH1A1SLC6A4SLC6A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227469-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2012-07-24 US disclosed
US-20090197879-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS BALAN CHENERA 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197879-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 LMNA 3886/4885ALDH1A1 3238/4885SLC6A4 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.